Court Allows Expert Testimony in Tylenol Autism Lawsuits
The decision permits scientists to testify in lawsuits alleging links between prenatal acetaminophen and autism.
Updated on Oct. 21, 2026 in Autism
Live Poll
Should pharmaceutical companies face lawsuits over disputed health claims linked to their widely used over-the-counter medications?
A federal appeals court has denied a request from companies to rehear a case regarding over 500 lawsuits alleging a link between prenatal acetaminophen use and autism or ADHD. This decision clears the way for previously excluded expert testimony to be included in ongoing multidistrict litigation.
Why it matters
The court's decision reverses a 2023 ruling that had barred scientific experts from testifying in these cases, marking a significant development for families pursuing legal action. The FDA is currently conducting its own investigation into whether prenatal exposure to the medication affects neurodevelopmental outcomes.
The Second Circuit panel rejected the exclusion of expert testimony, which used the Bradford Hill analysis to examine the correlation between medication use and developmental disorders. The scientific consensus on this potential link remains under active investigation by federal regulators.
The players
U.S. Court of Appeals for the Second Circuit
The federal appellate court that issued the ruling allowing expert testimony to proceed in the acetaminophen litigation.
Food and Drug Administration
The federal agency responsible for evaluating the safety of medications and currently investigating a potential link between acetaminophen and autism.
Robert F. Kennedy Jr.
A public figure who has issued reports detailing associations between acetaminophen usage and developmental disorders.
Denise Cote
A district judge who previously ruled to exclude expert witness testimony in the ongoing multidistrict litigation.
The details
The lawsuits center on claims that prenatal acetaminophen exposure contributes to neurodevelopmental issues. Expert witnesses involved in the litigation utilized the Bradford Hill analysis, a standard framework in epidemiology used to evaluate whether a statistical association between an exposure and an outcome suggests a causal relationship. The court ruled that this expert testimony should not be barred, disagreeing with the district judge's previous assessment that the evidence served only to confuse the jury.
Timeline
2023: Judge Denise Cote excluded five expert witnesses.
July 13, 2026: The Second Circuit reversed the exclusion of three expert witnesses.
October 16, 2026: The Second Circuit denied a request for a rehearing.
Health Landscape
This development follows the trajectory of the ongoing multidistrict litigation over prenatal acetaminophen exposure. It highlights the high threshold for scientific evidence in complex tort cases involving developmental disorders.
This legal update does not change clinical guidelines or current medical recommendations for pain management. Patients with concerns about prenatal medication exposure and child development are encouraged to discuss these questions directly with their obstetrician or pediatrician.
The takeaway
The court's ruling focuses on the admissibility of expert scientific evidence rather than reaching a final conclusion on health outcomes. Readers should monitor ongoing FDA investigations for official guidance regarding the safety of medications during pregnancy.
Further reading
For context on current understanding and research, visit Autism.
Live Poll
Should pharmaceutical companies face lawsuits over disputed health claims linked to their widely used over-the-counter medications?
